v3.26.3
STOCKHOLDERS’ EQUITY (DEFICIENCY) (Tables)
 12 Months Ended
Jun. 30, 2026
Equity [Abstract]  
SCHEDULE OF WARRANT EXERCISES

 

Series  Exercise Price   Warrants   Proceeds 
Series F Warrants  $15.00    16,866   $252,990 
Series G Warrants  $7.50    82,092    615,697 
Series H Warrants  $11.25    31,499    354,364 
Series J Warrants  $6.50    29,984    194,896 
Series K Warrants  $8.125    24,984    202,994 
         185,425   $1,620,941 
SCHEDULE OF OUTSTANDING STOCK PURCHASE WARRANTS

As of June 30, 2026, the Company had outstanding warrants for shares of common stock as follows:

 

   Shares of   Exercise Price   Latest
Description  Common Stock   per Share   Expiration Date
October 2022 Placement Agent Warrants   1,818   $10.00   October 31, 2027
October 2023 Placement Agent Warrants   2,358   $10.00   October 20, 2028
January 2024 Private Warrants   36,630   $273.00   February 1, 2028
January 2024 Placement Agent Warrants   1,831   $10.00   February 1, 2028
June 2024 Series B Warrants   37,712   $94.00   July 25, 2030 *
December 2024 Series C Warrants   78,153   $43.75   December 17, 2029
December 2024 Series D Warrants   39,076   $43.75   July 25, 2030
February 2025 Series E Warrants   93,760   $50.00   August 12, 2030
May 2025 Series F Warrants   129,613   $15.00   May 8, 2030
May 2025 Series G Warrants   64,387   $7.50   May 8, 2027
May 2025 Series H Warrants   50,593   $11.25   **
June 2025 Series I Warrants   123,636   $5.50   July 25, 2030
November 2025 Pre-funded Warrants   2,136,000   $0.0001   N/A
November 2025 Series J Warrants   2,765,400   $6.50   ***
November 2025 Series K Warrants   2,770,400   $8.13   ****
November 2025 Placement Agent Warrants   55,907   $8.13   November 12, 2030
November 2025 HCW Settlement Warrants   10,000   $10.00   January 12, 2028

 

*5,228 warrants expire June 24, 2029

 

**Expire 24 months following the initial exercise date

 

***Expires the earlier of (i) the 18-month anniversary of the Initial Exercise Date if FDA IND acceptance has not been received, or (ii) 31 days after notice of FDA IND acceptance, in each case adjusted to the next Trading Day; provided that under clause (ii) the date is extended until a registration statement and prospectus are available for 30 consecutive days.

 

****Expire on the 5-year anniversary of the Initial Exercise Date, or, if the Holder’s Series J Common Stock Purchase Warrant terminates pursuant to clause (ii) thereof prior to full cash exercise, the same Termination Date as the Series J Warrant, in each case adjusted to the next Trading Day; provided that the date is extended until a registration statement and prospectus are available for 30 consecutive days following notice of FDA IND acceptance.
SCHEDULE OF STOCK OPTION ACTIVITY

The following table summarizes option activity and related information for the years ended June 30, 2026, and 2025:

 

   Number of
Shares		   Weighted
Average
Exercise Price		   Weighted
Average
Remaining
Term in Years		  

Aggregate

Intrinsic Value

 
                 
Outstanding - June 30, 2024   45,269   $305.50    8.2                                     
                     
Granted   -    -           
Forfeited   -    -           
Exercised   -    -           
Expired   (464)   654.50           
Outstanding - June 30, 2025   44,805   $302.00    7.3      
                     
Granted   46,550    21.01           
Fractional shares   (14)               
Forfeited   (1,266)   76.33           
Exercised   -    -           
Expired   (5,094)   484.55           
Outstanding - June 30, 2026   84,981   $145.21    7.3   $- 
                     
Exercisable at June 30, 2026   27,625   $369.59    5.8   $- 
                     
Expected to vest at June 30, 2026   57,356   $35.95    8.0   $- 
SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS

 

   Year Ended 
   June 30, 2026 
     
Risk-free interest rate   3.9%
Volatility factor   109.7%
Dividend yield   0%
Expected option life (years)   5.9 
Weighted average grant date fair value  $16.45 
SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY

 

   Year Ended   Year Ended 
   June 30, 2026   June 30, 2025 
Outstanding at beginning of year   22,787    27,500 
Granted   24,950    - 
Forfeited   -    - 
Vested   (6,467)   (4,659)
Expirations   (1,453)   (54)
Fractional shares   -    - 
Outstanding at end of year   39,817    22,787